Skip to main content
The Markets by Proactive
Go to Proactive Australia

Archive

Mindset Pharma identifies additional drug candidates from 'Family 3' psilocybin compounds

Mindset Pharma identifies additional drug candidates from 'Family 3' psilocybin compounds

Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) CEO James Lanthier and Chief Scientific Officer Joseph Araujo joined Proactive to discuss the significance of synthesizing additional promising candidates from its Family 3 of next-generation drug candidates.

The duo say the group will initiate proof of concept preclinical studies to further measure the viability of these compounds as daily pro-cognitive take-home medication.